PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Anal PharmaPoint-Colorectal Cancer - Global Drug Foreca

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market
Analysis to 2025
ReportsWeb.com published “Colorectal Cancer” from its database. The report covers the market
landscape and its growth prospects over the coming years. The report also includes a discussion
of the key vendors operating in this market.
The colorectal cancer (CRC) market, considering the sales of both branded treatments and
generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025.
The main drivers of growth will be the expected increased number of diagnosed CRC incidence,
and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has
been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the
efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant
patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment
options and usually receive fewer lines of treatment compared with patients with RAS wild-type
disease. The CRC competitive landscape is going to experience a substantial change, following
the approval of pipeline agents exploiting novel mechanisms of actions, especially
immunotherapy. Some pipeline drug developers have invested heavily in the identification of
potential predictive biomarkers; therefore, these novel agents are expected to induce further
patient stratification and to add complexity to the CRC treatment algorithm, which will be also
reshaped by the discovery of the predictive value of tumor sidedness.
For more information about this report: http://www.reportsweb.com/pharmapoint-colorectal-
cancer-global-drug-forecast-and-market-analysis-to-2025 .
Key Findings
- The main driver of the growth of the CRC market will be the increasing CRC incident cases,
which is attributed to the aging population.
- The second strongest driver will be the launch of several efficacious pipeline drugs in the
metastatic setting, including immunotherapies that will enter the CRC landscape for the first
time, and novel molecular-targeted agents, such as BRAF-targeted therapies.
- To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate
higher efficacy, in terms of overall survival (OS), compared with available agents. For this
reason, almost all the new agents are expected to be positioned in the second- and third-line
settings, in which the standard-of-care hurdle is lower.